Separate from our Oncology/Immunology R&D and commercial operations, our Other Ventures segment operates in several countries in south-east Asia.
It mainly consists of:
Shanghai Hutchison Pharmaceuticals, a non-consolidated joint venture with a commercial team of about 2,200 staff managing the medical detailing and marketing of a range of own-brand prescription drug products across mainland China. This 50/50 joint venture is with Shanghai Pharmaceuticals, a leading pharmaceutical company in China.
Hutchison Sinopharm, a consolidated joint venture focused on providing commercial services for our own marketed drugs, as well as marketing third-party prescription drug products. This joint venture is 51% owned by HUTCHMED and 49% owned by Sinopharm, a leading distributor of pharmaceutical and healthcare products and a leading supply chain service provider in China.
Hutchison Healthcare, a wholly owned subsidiary which was established in 2001 and manufactures and sells health supplements.
Hutchison Sinopharm
Providing logistics services and marketing and distribution for prescription drugs manufactured by third parties.
In April 2014, we commenced operating Hutchison Sinopharm, a Shanghai-based Good Supply Practice-certified company focused on providing logistics services to, and distributing and marketing prescription drugs manufactured by third-party pharmaceutical companies in China.
We intend to expand Hutchison Sinopharm to operate as a full-service, third-party prescription drug commercialization company in China. In the longer term, our marketing network's ability to adapt to effectively market new drugs will help us launch any new oncology or immunology drugs developed by our oncology R&D engine.
Hutchison Sinopharm has entered into agreements with multinational and Chinese pharmaceutical manufacturers to market and distribute eight prescription products in China.
We also continue to operate Hutchison Sinopharm’s legacy business, which is focused on providing Shanghai logistics and distribution services to third-party pharmaceutical companies.
Shanghai Hutchison Pharmaceuticals
Manufacturing, marketing and distributing proprietary and licensed prescription drugs.
Shanghai Hutchison Pharmaceuticals primarily engages in the manufacture and sale of prescription drug products originally contributed by our joint venture partner, as well as third-party prescription drugs with a focus on cardiovascular medicine. Its proprietary products are sold under the "Shang Yao" brand, literally meaning "Shanghai pharmaceuticals," a trademark that has been used for over 40 years in the pharmaceutical retail market, primarily in Eastern China.
Shanghai Hutchison Pharmaceuticals sells its products and its third-party licensed prescription drugs directly to distributors, and also markets and sells third-party prescription drugs in collaboration with Hutchison Sinopharm.
Its medical sales representatives promote its products to doctors and purchasing managers in hospitals, clinics and pharmacies as part of its marketing efforts.
Shanghai Hutchison Pharmaceuticals has approximately 2,400 medical sales representatives and about 540 manufacturing employees across China.
Hutchison Healthcare
Our wholly owned subsidiary and is primarily engaged in the manufacture, marketing and distribution of health supplements in China. Hutchison Healthcare’s major product is Zhi Ling Tong DHA capsules, a health supplement made from algae DHA oil.